03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
16:39 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

FDA approves Adcetris for first-line classical Hodgkin's lymphoma

FDA approved an sBLA from Seattle Genetics Inc. (NASDAQ:SGEN) for Adcetris brentuximab vedotin (SGN-35) in combination with chemotherapy to treat adults with previously untreated stage III or IV classical Hodgkin's lymphoma. The company said it...
22:16 , Mar 20, 2018 |  BC Extra  |  Company News

FDA approves Adcetris for first-line classical Hodgkin's lymphoma

FDA approved an sBLA from Seattle Genetics Inc. (NASDAQ:SGEN) for Adcetris brentuximab vedotin in combination with chemotherapy to treat adults with previously untreated stage III or IV classical Hodgkin's lymphoma. The company said it is...
20:33 , Feb 2, 2018 |  BC Week In Review  |  Company News

Seattle Genetics buying Cascadian for $614M

Seattle Genetics Inc. (NASDAQ:SGEN) said it will acquire cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) for $10 per share in cash, or about $614 million. The price is a 69% premium to Cascadian's close of $5.90...
20:00 , Jan 31, 2018 |  BC Extra  |  Company News

Seattle Genetics buying Cascadian for $614M, raising cash

Seattle Genetics Inc. (NASDAQ:SGEN) said it will acquire cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) for $10 per share in cash, or about $614 million. The price is a 69% premium to Cascadian's close of $5.90...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
17:41 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Adcetris gets Priority Review for first-line classical Hodgkin's lymphoma

Seattle Genetics (NASDAQ:SGEN) said FDA accepted and granted Priority Review to an sBLA for Adcetris brentuximab vedotin (SGN-35) as first-line treatment for advanced classical Hodgkin's lymphoma. Its PDUFA date is May 1. Adcetris is approved in...